Broader Transparency on Risk-benefit Assessment of the Bial Trial in France

Journal Title: Journal of Advances in Medicine and Medical Research - Year 2016, Vol 15, Issue 7

Abstract

On 11 January 2016, a Phase I trial of an experimental fatty acid amide hydrolase inhibitor for pain developed by Bial-Portela was halted after six healthy volunteers were admitted to the University of Rennes Hospital in France. One volunteer died and four suffered severe neurological injuries. It is a dreadful reminder of the Tenegero trial that also hospitalized six volunteers in 2006. Three major similarities were observed between the Tegenero and Bial trials. The first similarity is related to the dosing interval protocol. There is a lack of information about whether the multiple-dose regimen included adequate time intervals between individuals receiving the drug. The second similarity is on the dosing calculation that was based on the ‘no adverse effect level’ (NOAEL). The third similarity is observed in terms of how there was no prior publication of preclinical findings in the public domain before the start of both trials. There have been calls for the full release of the Investigation Medicinal Product Dossier and the Investigator’s Brochure, as these data are critical to maximize patient safety in the future and should outweigh considerations of commercial confidentiality. Likewise, it is necessary for the Brest Regional Ethics Committee to release its documents, which captured the risk-benefit assessment in approving the Bial trial, for external scrutiny.

Authors and Affiliations

William Wei Lim Chin

Keywords

Related Articles

Placental Leucine Aminopeptidase/Oxytocinase Expression in Miscarriage

Objectives: To evaluate the role of placental leucine aminopeptidase (P-LAP) in miscarriage and searching to select the gene of this enzyme in miscarriage to exclude direct or indirect effects of abortion. Methods: Total...

Role of Hippocampal Neurogenesis in Regulation of Feeding Behavior during Withdrawal Period in Socialized and Isolated Rats

Introduction: Hippocampal neurogenesis is essential for cognitive functions like memory and learning. However, other functions of hippocampus are not well understood. We aimed to study the role of hippocampus in regulati...

Automated Glaucoma Detection Using Support Vector Machine Classification Method

Glaucoma is an eye disease that can result in blindness if it is not detected and treated in proper time. Increased intraocular pressure (IOP) of the fluid in the eye often causes glaucoma. Glaucoma is the second leading...

Knowledge and Awareness of Organ Donation and Brain Death among the Population in Al-Ahsa, Saudi Arabia

Background: Organ donation plays an important role in the treatment of cases of end organ failure and it has saved thousands of lives in the world. There is a worldwide shortage of donors in comparison to the need for tr...

Efficacy of Dental Floss Impregnated with Commercially Available Mouthwashes on Reduction of Supragingival Biofilm: A Randomized Single Blind Study

Aim: To evaluate the efficacy of dental floss impregnated with commercially available Chlorhexidine gluconate, Cetylpyredinium Chloride and Chlorine dioxide mouthwash on reduction of Supragingival Biofilm. Materials and...

Download PDF file
  • EP ID EP341437
  • DOI 10.9734/BJMMR/2016/26077
  • Views 81
  • Downloads 0

How To Cite

William Wei Lim Chin (2016). Broader Transparency on Risk-benefit Assessment of the Bial Trial in France. Journal of Advances in Medicine and Medical Research, 15(7), 1-7. https://europub.co.uk/articles/-A-341437